Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes

Early identification of severe dengue patients is important regarding patient management and resource allocation. We investigated the association of 10 biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, CRP) with the development of severe/moderate dengue (S/MD). We per...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:eLife 2021-06, Vol.10
Hauptverfasser: Vuong, Nguyen Lam, Lam, Phung Khanh, Ming, Damien Keng Yen, Duyen, Huynh Thi Le, Nguyen, Nguyet Minh, Tam, Dong Thi Hoai, Duong Thi Hue, Kien, Chau, Nguyen Vv, Chanpheaktra, Ngoun, Lum, Lucy Chai See, Pleités, Ernesto, Simmons, Cameron P, Rosenberger, Kerstin D, Jaenisch, Thomas, Bell, David, Acestor, Nathalie, Halleux, Christine, Olliaro, Piero L, Wills, Bridget A, Geskus, Ronald B, Yacoub, Sophie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Early identification of severe dengue patients is important regarding patient management and resource allocation. We investigated the association of 10 biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, CRP) with the development of severe/moderate dengue (S/MD). We performed a nested case-control study from a multi-country study. A total of 281 S/MD and 556 uncomplicated dengue cases were included. On days 1-3 from symptom onset, higher levels of any biomarker increased the risk of developing S/MD. When assessing together, SDC-1 and IL-1RA were stable, while IP-10 changed the association from positive to negative; others showed weaker associations. The best combinations associated with S/MD comprised IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1 for children, and SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163 for adults. Our findings assist the development of biomarker panels for clinical use and could improve triage and risk prediction in dengue patients. This study was supported by the EU's Seventh Framework Programme (FP7-281803 IDAMS), the WHO, and the Bill and Melinda Gates Foundation.
ISSN:2050-084X
2050-084X
DOI:10.7554/eLife.67460